Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06595069 · ClinicalTrials.gov registry record
A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients
A clinical trial of Hypercholesterolemia, sponsored by Novartis.
- Completed
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT06595069 is a study of Hypercholesterolemia that has completed, run by Novartis. The registered enrollment target is 600 participants, below the 807-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06595069, a study of Hypercholesterolemia, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a single-center, retrospective, observational study (non-interventional study with secondary use of data) among patients in a real-world setting. This study used the medical record data from patients in Yiling. Eligible patients who newly initiated inclisiran from 26 January 2022 to 21 August 2023 were included. The retrospective data up to the date of ethics committee approval (April 2024) was collected. The study team collected patient data using an electronic case report form (eCRF) from April 2024 to June 2024.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-04-30 |
| Est. Completion | 2024-07-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06595069
The ClinicalTrials.gov registry entry for NCT06595069 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 807-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (26% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 0 interventions.
NCT06595069 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06595069 about?
NCT06595069 is a clinical study titled "A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients". This was a single-center, retrospective, observational study (non-interventional study with secondary use of data) among patients in a real-world setting. This study used the medical record data from patients in Yiling. Eligible patients who newly initiated inclisiran from 26 January 2022 to 21 Aug...
What is the current status of trial NCT06595069?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2024-04-30. Estimated completion is 2024-07-10.
What conditions does trial NCT06595069 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
Who is sponsoring clinical trial NCT06595069?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06595069 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics of Butyrate Tablet BKR-017
RECRUITING
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
RECRUITING · NA
-
Pharmacogenomic Informed Statin Prescribing
RECRUITING · NA
-
Causes and Natural History of Dyslipidemias
RECRUITING
-
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.